Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: Cardinal Health operates four reportable segments: Pharmaceutical Distribution and Provider Services, Medical Products and Services, Pharmaceutical Technologies and Services, and Clinical Technologies and Services. The company provides integrated healthcare solutions, including pharmaceutical distribution, medical products manufacturing, and clinical technologies.
Key Financial Metrics
| Metric (in millions) | Q3 2005 | Q3 2004 |
|---|---|---|
| Revenue | $19,373.4 | $17,792.3 |
| Gross Margin | $1,213.2 | $1,090.5 |
| Operating Earnings | $372.4 | $362.3 |
| Net Earnings | $228.3 | $213.3 |
| Diluted EPS | $0.53 | $0.49 |
| Cash from Operations | $724.0 | $895.0 |
| Cash and Equivalents (End of Period) | $1,976.9 | $1,152.3 |
| Total Debt (Current + Long-term) | $2,609.3 | Not explicitly stated for Q3 2004 |
Note: Total Debt calculated as Current portion of long-term obligations ($405.3M) + Long-term obligations ($2,204.0M) as of Sept 30, 2005.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 9% year-over-year, driven by higher sales volume across all segments, new customer agreements, and pharmaceutical price increases.
- Equity-Based Compensation: Operating earnings were significantly impacted by the adoption of SFAS No. 123(R). Equity-based compensation expense rose to $82.9 million in Q3 2005 from $2.1 million in Q3 2004. This included a $32.6 million charge related to Stock Appreciation Rights (SARs) granted to the CEO.
- Vendor Credit Charge: The Pharmaceutical Distribution segment recorded a $31.8 million charge due to the discovery of unprocessed vendor credits from prior years, attributed to system programming and data entry errors.
- Segment Performance:
- Clinical Technologies: Operating earnings surged 88% due to strong Pyxis product sales.
- Pharmaceutical Technologies: Operating earnings declined 42% due to underutilized sterile manufacturing capacity and competitive pricing.
- Medical Products: Operating earnings increased 21%, aided by a favorable comparison to a $16.4 million latex litigation charge taken in the prior year.
- Special Items: Total special items decreased to $22.7 million in 2005 from $31.9 million in 2004, primarily due to lower merger-related costs ($7.8M vs $16.9M).
Guidance, Outlook, Risks, and Contingencies
- Restructuring Outlook: The company expects its global restructuring program to improve operating earnings by approximately $190 million in fiscal 2006. Future costs for restructuring and integration are estimated at $252.7 million.
- Equity Compensation Forecast: Management expects equity compensation expense for fiscal 2006 to range between $215 million and $230 million.
- Legal and Regulatory Risks:
- SEC Investigation: The company is subject to a formal SEC investigation regarding accounting and financial reporting matters. A $25 million reserve was recorded in fiscal 2005, but the company cannot predict the final outcome or potential additional costs.
- Litigation: Numerous shareholder derivative actions, federal securities actions, and ERISA lawsuits are pending. The company also faces an FTC investigation into potential anticompetitive practices and inquiries from state Attorneys General (NY, IL).
- Discontinued Operations: The sterile pharmaceutical manufacturing business in Humacao, Puerto Rico, has been classified as discontinued operations, resulting in a net loss of $6.3 million for the quarter.
- Legislative Risk: Proposed Medicaid reform legislation could adversely affect reimbursement formulas for retail pharmacies, potentially impacting the Pharmaceutical Distribution segment starting in 2007.
Investor Verification Checklist
- SEC Investigation Resolution: Monitor the status of settlement discussions with the SEC and the adequacy of the $25 million reserve.
- Vendor Credit Controls: Verify the implementation of remediation plans for the internal control deficiencies regarding vendor credit processing.
- Equity Compensation Impact: Track the actual equity compensation expense against the $215M-$230M fiscal 2006 guidance.
- Specialty Distribution Customer Loss: Assess the impact of the largest Specialty Distribution customer beginning self-distribution on January 1, 2006.
- Restructuring Execution: Review progress on the global restructuring program and the realization of the projected $190 million earnings benefit.